CERAMENT V remodels to host bone within 6‐12 months, and is injectable and flowable, offering complete dead space management. In addition, it is the first and only CE‐marked vancomycin‐eluting synthetic bone substitute on the market today and ideal for use in indications where infection may be present or of concern.
Elution that is reliable and consistent
Irrespective of whether CERAMENT V is injected, molded or formed into beads, the elution profile of vancomycin is the same.
The patented mixing and injecting device ensures a homogeneous distribution of antibiotic, whilst the material properties of CERAMENT means that all of this antibiotic is made available for elution and delivered in a controlled fashion.
REFERENCES
S038/2013. Data on file, BONESUPPORT AB, Sweden
Lindberg. In vitro characterization of a vancomycin eluting injectable bone graft substitute with examination of concomitant bone remodeling in rabbit. Presentation given at EBJIS 2014.
A neutral pH that doesn't interfere with antibiotic activity
CERAMENT V paste has been designed to have a pH close to neutral pH (6.6 – 7.0), so it does’t reduce antibiotic activity. Vancomycin is effective in the pH range 6.4 – 8.
In vitro studies have shown that CERAMENT V discs exposed to Staphylococcus aureus (ATCC 6538) have a clear zone of inhibition for at least 18 days*.
*Note: at this point the zone of inhibition remained over 12mm, but it was no longer feasible to move beads without disintigration.
REFERENCES
S006/2013. Data on file, BONESUPPORT AB, Sweden
S016/2013. Data on file, BONESUPPORT AB, Sweden
S038/2013. Data on file, BONESUPPORT AB, Sweden
S061/2012. Data on file, BONESUPPORT AB, Sweden
Lindberg. In vitro characterization of a vancomycin eluting injectable bone graft substitute with examination of concomitant bone remodeling in rabbit. Presentation given at EBJIS 2014.
Vancomycin elution with a high initial peak, that remains above the minimum inhibitory concentration (MIC) for most vancomycin-sensitive microorganisms for at least 28 days in in vitro tests
It is essential to have a vancomycin concentration above MIC for a clinically relevant period of time, and in vitro studies have shown vancomycin elution from CERAMENT V has a high initial peak (>3000mg/L), and remains above MIC for at least 28 days.
REFERENCES
S038/2013. Data on file, BONESUPPORT AB, Sweden
Soriano et al. Influence of vancomycin minimum inhibitory concentration on the treatment of Methicillin-Resistant Staphylococcus aureus bacteremia. Clinical Infectious Diseases 2008; 46:193–200
Lindberg. In vitro characterization of a vancomycin eluting injectable bone graft substitute with examination of concomitant bone remodeling in rabbit. Presentation given at EBJIS 2014.
http://emedicine.medscape.com/article/2090484-overview
Colding-Rasmussen et al, In vivo and in vitro evaluation of vancomycin and gentamicin elution from bone graft substitutes, poster at EBJIS 35th Annual Meeting, 2016, Oxford, UK
A high local concentration of vancomycin, without high serum vancomycin levels
In vitro studies have shown that CERAMENT V offers vancomycin levels up to 3,000 times the minimum inhibitory concentration (MIC) for Methicillin-Resistant Staphylococcus aureus (MRSA).
In patients who underwent tumor resection arthroplasty with CERAMENT V implanted into the bone void, the mean blood plasma concentration of vancomycin measured was 0.3µg/mL (range 0.0 – 1.6µg/mL), well below the trough toxicity level of 10-20 µg/mL.
REFERENCES
S038/2013. Data on file, BONESUPPORT AB, Sweden
Soriano et al. Influence of vancomycin minimum inhibitory concentration on the treatment of Methicillin-Resistant Staphylococcus aureus bacteremia. Clinical Infectious Diseases 2008; 46:193–200
Lindberg. In vitro characterization of a vancomycin eluting injectable bone graft substitute with examination of concomitant bone remodeling in rabbit. Presentation given at EBJIS 2014.
http://emedicine.medscape.com/article/2090484-overview
Colding-Rasmussen et al, In vivo and in vitro evaluation of vancomycin and gentamicin elution from bone graft substitutes, poster at EBJIS 35th Annual Meeting, 2016, Oxford, UK
RELATED INFORMATION
READ MORE
REFERENCES
CERAMENT™|V Instructions for use – IFU0017-03
S038/2013. Data on file. BONESUPPORT AB, Sweden
Yang et al. In vitro elution characteristics of vancomycin in a composite calcium phosphate/calcium sulfate bone substitute. HSSJ (2012) 8:129–132.
Lindberg. In vitro characterization of a vancomycin eluting injectable bone graft substitute with examination of concomitant bone remodeling in rabbit. Presentation given at EBJIS 2014.
http://www.rsc.org/Education/EiC/issues/2012March/vancomycin.asp